Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes
mayo 24, 2024
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty
The COPD Foundation is kicking off its 20th anniversary year with exciting news! Bronchiectasis and NTM 360, a division of the COPD Foundation, is thrilled to announce its journey to establish a Bronchiectasis and NTM Care Center Network.
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
We explore this concept and look at atopic dermatitis, chronic rhinosinusitis with nasal polyps, etc., as treatable traits of asthma and how these can be managed.
Since 2001 the GOLD publishes and updates every year a document that recommends how to best diagnose and manage COPD. The GOLD 2024 document has just been released and is available for free download in the GOLD website.
TT guided asthma management for 10 weeks reduced T2 inflammation.
Join the international educational symposium on Chronic Obstructive Pulmonary Disease (COPD). 2023 marks the 8th Annual GOLD International COPD Conference.